Kingstray Biotechnology (01548.HK): The legendary potential "same-class first-in-class" intracellular CD19/CD20 dual-target CAR-T therapy LB2501 has obtained clinical conceptual verification in relapsed/refractory B-cell non-Hodgkin lymphoma.

Zhtng Cijng APP news, Kingsway Biotech (01548.HK) announced that its affiliate, Legend Biotech Limited (Legend), whose shares are listed on the Nasdaq Global Select Market in the form of American Depositary Shares, issued a press release on June 14, 2026 (New York time) announcing the first clinical concept verification data of its investigational in vivo CD19/CD20 dual-target CAR-T cell therapy LB2501 for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/RB-NHL). The study results were presented today at the latest breakthrough session of the 2026 European Hematology Association (EHA) Annual Meeting (Abstract Number: LB5006). In this ongoing Phase I study, a single infusion of LB2501 achieved dose-dependent expansion of in vivo CAR-T cells without the need for lymphodepletion. At a higher dose level (DL2), LB2501 achieved a 100% objective response rate (ORR) (6/6) and an 83.3% complete response rate (CR) (5/6), with all responses still ongoing at the time of data cutoff. LB2501 also demonstrated favorable safety characteristics, with no reports of dose-limiting toxicity (DLT), serious adverse events (SAE), immune effector cell-associated neurotoxicity syndrome (ICANS), or deaths.